

Notification Date: January 14, 2025 Effective Date: Immediately

MLH1 Hypermethylation and BRAF Mutation Analysis, Tumor

Test ID: BRMLH

Explanation: As shown below, BRMLH Ordering Guidance has been updated.

Current Ordering Guidance

This test is **not recommended** as a first-tier screening for Lynch syndrome. Order TMSI / Microsatellite Instability, Tumor and IHC / Mismatch Repair (MMR) Protein Immunohistochemistry Only.

This test will only be performed on colon tumors demonstrating loss of MLH1 protein expression.

New Ordering Guidance

This test is **not recommended** as a first-tier screening for Lynch syndrome. Order TMSI / Microsatellite Instability, Tumor and IHC / Mismatch Repair (MMR) Protein Immunohistochemistry Only.

This test will only be performed on colon tumors demonstrating loss of MLH1 protein expression.

If the MMR immunohistochemistry (IHC) results for MLH1 and/or PMS2 suggest possible tumor heterogeneity, are ambiguous, or unusual, the physical IHC stains will be required to optimize the area of tissue selected for testing and for interpretation of the results. If IHC stains are required and not sent with the specimen, a request will be submitted to provide the IHC stains which will result in a slight delay.

Questions

Contact Michelle Raths, Laboratory Resource Coordinator at 800-533-1710.